The novel immunosuppressant FTY720 has been demonstrated to elicit immunomodulating effects via interaction with the G-protein coupled receptor S1P(1). FTY720 induced agonism at the S1P(3) receptor, however, has been shown to result in mild bradycardia, a minor side-effect of initial FTY720 therapy. This report describes the synthesis of several potent 4(5)-phenylimidazole-based S1P(1) receptor agonists that are accompanied by poor agonist activity at S1P(3). For instance, compound 20 displayed an EC(50)=4.7+/-1.3 nM at the S1P(1) receptor and EC(50)=780+/-1.3 nM at the S1P(3) receptor using a [gamma-(35)S]GTP-binding assay as compared to phospho-FTY720 (S1P(1): EC(50)=1.3+/-1.3nM, S1P(3): EC(50)=2.0+/-2.4 nM).

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2005.05.097DOI Listing

Publication Analysis

Top Keywords

s1p1 receptor
12
receptor agonists
8
s1p3 receptor
8
receptor
6
s1p1
5
synthesis 45-phenylimidazole-based
4
45-phenylimidazole-based analogues
4
analogues sphingosine-1-phosphate
4
fty720
4
sphingosine-1-phosphate fty720
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!